PYC Therapeutics Limited (AU:PYC) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
PYC Therapeutics is advancing its investigational drug PYC-003 into human trials, aiming to address the unmet needs of patients with Autosomal Dominant Polycystic Kidney Disease. Recent pre-clinical studies show promising results, with effective gene expression control and a favorable safety profile. The trials are expected to start in early 2025, marking a significant step for the company in tackling genetic diseases.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.